Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab

Anxiety Clinical Trial

— RELAX  

Official title:

Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01428115
• Other study ID #: P12-705
• Status: Completed
• Phase: N/A
• First received: September 1, 2011
• Last updated: October 31, 2014
• Start date: December 2011
• Est. completion date: October 2013

Study information

• Verified date: October 2014
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Federal Office for Safety in Health Care
• Study type: Observational

Clinical Trial Summary

It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.

Such findings have to be taken into consideration when making an educated guess that psychological factors such as depression and anxiety in particular interact with the course of Crohns disease. Therefore the treatment of the underlying disease may have a significant influence on the level of psychological disorders.

Several studies have shown that treatment with tumor necrosis factor alpha (TNF-α) antibodies ameliorates the emotional/psychological status of patients, however the impact of adalimumab therapy on anxiety correlated with the status of inflammatory bowel disease (IBD) remains unclear.

The primary objective of this study was to describe and evaluate changes in levels of anxiety assessed by validated patient questionnaires after 6 months of treatment with adalimumab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients for whom Adalimumab (Humira) therapy is indicated and has been prescribed according to the product label and who meet the following criteria:

• Male and female patients aged 18 to 65 years suffering from severe active Crohns Disease, attending a routine medical visit.

• Able to complete questionnaires.

• Patients with status active severe Crohns disease which required immunosuppressive treatment

• Patients must fulfil international and national guidelines for the use of a biologic therapies in Crohns Disease (Chest X-ray and interferon gamma release assay (IGRA) or PPD (purified protein derivative)-skin test negative for tuberculosis).

• Patients have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

• Patients who have been prescribed in line with the European Summary of Product Characteristics (SMPC)

Exclusion Criteria:

• The following patients will not be included in this observational study:

• Previous therapy with TNF-a blocker within the last 8 weeks

• Active Central Nervous System opportunistic infections or Central Nervous System malignancies.

• History of Cerebrovascular Accident

• Abuse of illicit substances (such as psychoactive drugs) within the previous 3 months

• Change of medication-based treatment of generalized anxiety and panic disorder, psychiatric disorder

• No informed consent

• Contraindication to adalimumab (Humira) therapy according to the SMPC

• Current or planned pregnancy

• Lactation according to SMPC

• Planned change of site within the next 24 weeks.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders
• Crohn Disease
• Severe Crohn's Disease

Locations

Country	Name	City	State
Austria	Site Reference ID/Investigator# 64830	Graz
Austria	Site Reference ID/Investigator# 64832	Innsbruck
Austria	Site Reference ID/Investigator# 64829	Linz
Austria	Site Reference ID/Investigator# 64831	Salzburg
Austria	Site Reference ID/Investigator# 64828	St. Poelten
Austria	Site Reference ID/Investigator# 79613	St. Veit/Glan
Austria	Site Reference ID/Investigator# 47342	Vienna
Austria	Site Reference ID/Investigator# 64833	Vienna

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie (prior sponsor, Abbott)	Raffeiner GmbH

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in State Trait Anxiety Index (STAI) State Scores From Baseline to After 6 Months of Treatment With Adalimumab	The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.	Baseline and Visit 3 [Month 6]	No
Primary	Change in State Trait Anxiety Index (STAI) Trait Scores From Baseline to After 6 Months of Treatment With Adalimumab	The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.	Baseline and Visit 3 [Month 6]	No
Primary	Change in Hospital Anxiety and Depression Score (HADS) - Anxiety, From Baseline to After 6 Months of Treatment With Adalimumab	HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.	Baseline and Visit 3 [Month 6]	No
Primary	Change in Hospital Anxiety and Depression Score (HADS) - Depression, From Baseline to After 6 Months of Treatment With Adalimumab	HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.	Baseline and Visit 3 [Month 6]	No
Secondary	Short Inflammatory Bowel Disease Questionnaire (sIBDQ) Scores by Visit	The sIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The sIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). The scores are summed up and divided by 10 for a mean score ranging from 1 (poor QoL) to 7 (good QoL). A higher score indicates a better HRQoL.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No
Secondary	Harvey-Bradshaw Index (HBI) Scores by Visit	Harvey-Bradshaw Index (HBI) is for use in the assessment and quantification of symptoms and the present level of disease activity of patients with Crohn's disease. It is a validated clinical index for Crohn's disease, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25 with higher scores indicating higher disease activity. The scores were classified as follows: less than 5 is remission, 5 to 7 is mild, 8 to 16 is moderate, and greater than 16 is severe.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No
Secondary	State Trait Anxiety Index (STAI) State Scores by Visit	The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No
Secondary	State Trait Anxiety Index (STAI) Trait Scores by Visit	The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No
Secondary	Hospital Anxiety and Depression Score (HADS) - Anxiety Scores by Visit	HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No
Secondary	Hospital Anxiety and Depression Score (HADS) - Depression Scores by Visit	HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.	Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]	No

External Links

•   Link